First Patients Dosed in Trial of Pharmaxis Scar Reduction Drug

31st Jan 22

Release Date: 31/01/2022 8:26am

  • Collaboration with research team led by Professor Fiona Wood AM doses first patients in trial of 50 patients with established scars
  • 3-month placebo-controlled study to report safety and tolerability endpoints as well as measures of scar structure and appearance in 2H 2022
  • PXS-6302 is a first in class topical inhibitor of the lysyl oxidase enzymes that are involved in formation and maintenance of scars; a potential breakthrough treatment for patients with problematic scars in a market estimated at US$3.5 billion per year

Read full media release - pdf

Categories: News and Media